Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
出版年份 2016 全文链接
标题
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
作者
关键词
Imatinib, Chronic Myeloid Leukemia, Dasatinib, Nilotinib, Chronic Myeloid Leukemia Patient
出版物
Molecular Diagnosis & Therapy
Volume 20, Issue 4, Pages 315-333
出版商
Springer Nature
发表日期
2016-05-25
DOI
10.1007/s40291-016-0208-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
- (2015) Andreas Hochhaus et al. ANNALS OF HEMATOLOGY
- A review of the European LeukemiaNet recommendations for the management of CML
- (2015) Michele Baccarani et al. ANNALS OF HEMATOLOGY
- Natural course and biology of CML
- (2015) Bradley Chereda et al. ANNALS OF HEMATOLOGY
- Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
- (2015) Simona Soverini et al. Clinical Lymphoma Myeloma & Leukemia
- Chronic myeloid leukaemia
- (2015) Jane F Apperley LANCET
- Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche
- (2014) D. S. Krause et al. BLOOD
- The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells
- (2014) C. I. Kobayashi et al. BLOOD
- Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition
- (2014) K. P. Ng et al. BLOOD
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
- (2014) Yaoyu Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia
- (2014) Jacob Vine et al. LEUKEMIA & LYMPHOMA
- The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia
- (2014) A. L. MacLean et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Small molecule Me6TREN mobilizes hematopoietic stem/progenitor cells by activating MMP-9 expression and disrupting SDF-1/CXCR4 axis
- (2013) J. Zhang et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
- (2013) Maya Koren-Michowitz et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients
- (2013) Alessandra Iurlo et al. European Journal of Internal Medicine
- Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia
- (2012) Luciana Nardinelli et al. ACTA HAEMATOLOGICA
- Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
- (2012) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
- (2012) A. Giannoudis et al. BLOOD
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
- (2012) S. Angelini et al. HAEMATOLOGICA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
- (2011) A. Kumari et al. BLOOD
- Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
- (2011) A. R. Ibrahim et al. BLOOD
- Molecular Pathways: BCR-ABL
- (2011) D. Cilloni et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to BCR–ABL kinase inhibitors
- (2011) Joana M. Diamond et al. LEUKEMIA & LYMPHOMA
- Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia?
- (2010) S. Dulucq et al. BLOOD
- Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib
- (2010) W. Deenik et al. BLOOD
- Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
- (2010) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
- (2010) Naoto Takahashi et al. JOURNAL OF HUMAN GENETICS
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1
- (2010) D L White et al. LEUKEMIA
- Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia
- (2010) Margherita Maffioli et al. LEUKEMIA RESEARCH
- Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia
- (2010) Ling-Na Ni et al. MEDICAL ONCOLOGY
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
- (2009) D. H. Kim et al. CLINICAL CANCER RESEARCH
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular biology of bcr-abl1-positive chronic myeloid leukemia
- (2008) A. Quintas-Cardama et al. BLOOD
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
- (2008) S. Dulucq et al. BLOOD
- An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
- (2008) A Agarwal et al. LEUKEMIA
- OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients
- (2008) Otto Zach et al. LEUKEMIA & LYMPHOMA
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now